Tags : Celiac Disease

Takeda Acquires Exclusive Worldwide License Rights for COUR’s CNP-101 to

Shiwani Sharma October 22, 2019

Shots: COUR to receive ~$420M milestone and royalties on sales of licensed products. Takeda exercised its option to acquire the exclusive global license to develop and commercialize TAK-101/CNP-101 following P-IIa proof-of-concept placebo-controlled study In Dec’2015, Takeda and COUR collaborated to develop therapies for celiac disease, provided Takeda an exclusive option to acquire a WW license […]Read More

Innovate Biopharmaceuticals Initiates P-III Clinical Study for Celiac Disease

Tuba Khan June 10, 2019

Shots: Innovate Biopharmaceuticals announces the initiation of P-III clinical study of INI-202 for Celiac disease with its expected screening & enrollment updates in next few months The P-III clinical study is the one of key event for addressing needs of Celiac patients with continued symptoms despite being on a gluten-free diet Innovate focuses on developing […]Read More

Amgen Out-Licenses its AMG 714 (PRO-015) Candidate to Provention to

Shiwani Sharma November 5, 2018

Shots: Amgen to make $20M investment in Provention and also has option to license AMG-714 (after completion of P-IIb), if exercised will pay $150M as upfront plus milestones and royalties to Provention Provention to fund and conduct the P-IIb trial for PRO-015 (AMG 714) and holds commercialization rights (if not exercised by Amgen) while giving […]Read More

Roche Report Mixed Results of Etrolizumab in P-III Studies for Patients with Moderately to Severely Active Ulcerative Colitis

Roche’s Evrysdi (risdiplam) Receives the US FDA’s Approval for SMA in Adults and Children

AstraZeneca Collaborates with Daiichi Sankyo to Evaluate the Combination of Patritumab Deruxtecan (U3-1402) + Tagrisso for EGFR-Mutated Non-Small Cell Lung Cancer

Roche’s Tecentriq (atezolizumab) + Paclitaxel Fail to Meet the Primary Endpoint in P-III IMpassion131 Study for Patients with Metastatic Triple-Negative Breast Cancer

Teva and Alvotech Collaborate to Commercialize Five Biosimilar Candidates in the US

Henlius and Accord’s Zercepac (trastuzumab, biosimilar) Receive the EMA Approval for HER2-Positive Breast Cancer and Gastric Cancer

Vela Diagnostics’ ViroKey SARS-CoV-2 RT-PCR Test Receives the US FDA’s Emergency Use Authorization

Moderna Prices its COVID-19 Vaccine at $32-$37 per Dose for Smaller Volume Agreements

Tags : Celiac Disease

Takeda Acquires Exclusive Worldwide License Rights for COUR’s CNP-101 to

Innovate Biopharmaceuticals Initiates P-III Clinical Study for Celiac Disease

Amgen Out-Licenses its AMG 714 (PRO-015) Candidate to Provention to

Latest Posts

Boehringer Ingelheim Acquires GST to Boost its Stem Cell Capabilities in Animal Health

Roche Report Mixed Results of Etrolizumab in P-III Studies for Patients with Moderately to Severely Active Ulcerative Colitis

The US FDA Approves Guardant360 CDx as the First Liquid Biopsy NGS Assay to Identify EGFR Mutations in Non-Small Cell Lung Cancer

Roche’s Evrysdi (risdiplam) Receives the US FDA’s Approval for SMA in Adults and Children

Tags : Celiac Disease

Latest Posts

Categories

Related Topics